NR5A2 and type 1 diabetes mellitus: Collectively, our findings indicate that the pharmacological activation of LRH‐1/NR5A2 reduces the expression of key pro‐inflammatory cell surface markers in T1D M1 and mDCs with a concomitant reduction in the secretion of several pro‐inflammatory cytokines/chemokines in T1D M1, mDCs and iDCs.